ERLOTINIB GLENMARK 100mg tablets medication leaflet

L01EB02 erlotinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

Erlotinib is a medication used in the treatment of certain types of lung cancer and advanced pancreatic cancer. It works by blocking a protein involved in the growth and multiplication of cancer cells, thus helping to slow disease progression.

Erlotinib is administered orally as tablets, once daily, according to the oncologist's instructions. The dose may be adjusted depending on the patient's response to treatment and any side effects.

Side effects may include skin rashes, diarrhea, nausea, fatigue, or, rarely, liver dysfunction and severe allergic reactions. Medical monitoring is necessary throughout the treatment.

Erlotinib is an effective option for patients with advanced lung or pancreatic cancer, offering the chance to prolong survival and improve quality of life.

General data about ERLOTINIB GLENMARK 100mg

Substance: erlotinib

Date of last drug list: 01-03-2022

Commercial code: W63790001

Concentration: 100mg

Pharmaceutical form: tablets

Quantity: 30

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: REMEDICA LTD. - CIPRU

Holder: GLENMARK PHARMACEUTICALS S.R.O. - REPUBLICA CEHA

Number: 10083/2017/01

Shelf life: 3 years

Concentrations available for erlotinib

100mg, 150mg, 25mg, 50mg

Other substances similar to erlotinib